An experimental treatment for Type 1 spinal muscular atrophy (SMA) has reached its primary endpoint in a pivotal trial of infants, paving the way for a US regulatory decision by late May, according to the developer Roche. The drug, risdiplam, is a small molecule that works by increasing the amount of protein produced by the survival motor neuron-2 (SMN2) gene.
